slides · global inventory
Sparkline
Arc collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 22,963
Current window 15,181-15,210
Pages 766
Rows per page 30
Arc
15,181-15,210 of 22,963
32
The diagram is a classic flywheel or continuous improvement loop.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
33
Includes a process flow diagram for Chemical Synthesis, Compound Management, and Biological Testing.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
34
The slide uses a flywheel-style circular process diagram to show the integration of digital design and physical lab automation.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
35
The slide uses an isometric technical illustration to depict a modular lab setup.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
36
Uses a contrast-pairs framework to highlight the shift from common/similar processes to unique/varied processes.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
37
The slide uses a process flow diagram to map specific robotic solutions to different stages of laboratory automation.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
38
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
39
The slide uses a circular process flow to represent a proprietary R&D pipeline.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Solution (Provide relief)1 hit
41
The slide uses Kaplan-Meier curves to demonstrate clinical efficacy of the platform's drug prioritization.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
42
The slide uses a converging timeline/process flow to show how different patient types (Ovarian cancer vs AML) feed into a unified precision medicine testing platform.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
43
Uses a complex heatmap/dot-plot visualization to show drug sensitivity across different samples and cell lines.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
44
The slide uses a small multiples approach to show individual patient responses, then aggregates them into two groups (I and II) to demonstrate differential sensitivity.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
45
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
46
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
47
The slide uses a molecular visualization as a background element to represent the drug target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
48
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
49
The slide uses a human anatomy diagram to map specific cancer types to their locations, providing a visual representation of the addressable market.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
50
Includes a biological pathway diagram and a list of potential cancer indications.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
51
The slide uses a three-column layout to define the target product profile (TPP) for a CDK7 inhibitor.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
52
The slide uses a color-coded heatmap to visualize performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
53
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
54
The slide uses two distinct charts to correlate drug exposure time with physiological toxicity (body weight change).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
55
The chart displays sensitivity across 60+ samples. The right side shows a volcano plot for pathway analysis and a conceptual diagram for combination testing.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
56
The slide uses a waterfall plot for single-agent sensitivity and a heatmap for combination synergy, highlighting specific patient response rates for different mechanisms of action.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
57
Includes a Venn diagram and two line charts showing Log2FoldChange vs concentration.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
58
The slide features a 3D molecular visualization of the protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
59
The chart compares % Reduction PLN Weight across different doses of EXS4318 versus a failed competitor drug.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
60
The slide uses a traffic-light color coding system to highlight the superior profile of EXS4318.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
61
The slide uses a process-flow layout with icons representing each stage.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
62
The background features a 3D molecular visualization, likely representing the LSD1 protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit